Brief: Kiromic Announces FDA Ind Submission First-In-Human, Ai Derived Off-The-Shelf Isomesothelin Gamma Delta Car T-Cell Therapy
24/05/2021 13:24
May 24 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC ANNOUNCES FDA IND SUBMISSION FIRST-IN-HUMAN, AI
DERIVED
OFF-THE-SHELF ISOMESOTHELIN GAMMA DELTA CAR T-CELL THERAPY, 30
DAYS BEFORE THE END OF THE SECOND QUARTER
Source text for Eikon: ID:nBwbH9Flka
Further company coverage: KRBP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site